Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study

Recruitment & Eligibility

Status: ot Recruiting

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

-Age: 25 to 80 years, inclusive.
-Male or female subjects with probable or confirmed ALS (revised international El Escorial criteria, Forbes et al., 2001).
-Patients presenting first motor deficits due to ALS for a maximum of three years at the first consultation in an ALS centre.
-Patients monitored for at least 6 months in an ALS centre or for whom the previous monitoring parameters are available (excepted for MIP and SNIP).
-Patients who have lost at least 5 points on the ALSFRS-R during the last 12 months or at least 2 points during the preceding 6 months
-Patients who have been treated with riluzole for at least 3 months at a stable dose. In case of intolerance to this product or refusal for this treatment, patients who have not been treated with riluzole for at least 1 month.
-For patients with spinal form (onset of the disease affecting limbs) or respiratory form, slow vital capacity > 60% of predicted value.
-For patients with a bulbar form, slow vital capacity > 60% of theoretical value or, if spirometry not assessable (severe bulbar disability), patient should not have significant abnormality in both nocturnal capnography and nocturnal oximetry (median pCO2 < 52 mmHg, SaO2 < 90% less than 5% of the time during night) less than 3 months prior inclusion.
-Patients who are willing to give written consent (or oral consent in the presence of a trusted person if the patient is no longer able to write)
-Patients likely to be able to participate in all scheduled evaluation and complete all required study procedures (except for spirometry in bulbar patients with severe disability).

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

-Patients on non-invasive ventilation for respiratory insufficiency due to ALS for more than 10 hours a day
-Patients with an ALSFRS-R score at inclusion of < 20 (maximum score without disability = 48)
-Patients who have lost less than 5 points on the ALSFRS-R during the last year or less than 2 points during the preceding 6 months
-Patients with a gastrostomy
-Patients who have lost more than 15% of their ideal weight
-Patient with dyspnoea at rest or with the least effort (score < 3 on the dyspnoea item of the ALSFRS-R)
-Patients with dementia
-Patient with severe or rapidly progressive form of ALS for whom the investigator estimates the life expectancy less than 3 months
-Patients with another progressive disease that has not been stabilized at the time of inclusion
-Patients with cancer, except basal cell carcinoma, for less than 5 years, or who require continuous treatment for cancer even if it is older
-Pregnant women.
-Subject who are not covered by a social security scheme.
-Subject under temporary or permanent Judicial Protection.
-Contraception: Both male subjects, and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel), must commit to using two highly effective method of birth control for the duration of the study and for two months after the treatment termination.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Investigation of the safety of biotin in ALS;<br> Secondary Objective: Investigation of the effect of biotin on the parameters of clinical progression and on the prognosis of ALS<br> ;<br> Primary end point(s): Safety<br> -Incidence of adverse events<br> -Laboratory testing abnormalities<br> -RBC, WBC, platelets<br> -Ferritin, CPK<br> -Electrolytes, creatinine, glycaemia<br> -AST, ALT, bilirubin, GGT, alkaline phosphatase<br> -Triglyceride, cholesterol<br> -Haemostasis: APPT, PT<br> ;Timepoint(s) of evaluation of this end point: every 3-month

Secondary Outcome Measures

Name	Time	Method
<br> Secondary end point(s): Efficacy<br> -Motor disability (ALSFRS-R score)<br> -Disease severity<br> -Respiratory parameters<br> -Slow vital capacity (SVC)<br> -Maximal inspiratory pressure (MIP)<br> -Sniff nasal inspiratory pressure (SNIP).<br> -Weight<br> ;Timepoint(s) of evaluation of this end point: every 3-month

Related Trials